Compounds > radezolid
Page last updated: 2024-11-12

radezolid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11224409
CHEMBL ID455461
SCHEMBL ID1035776
SCHEMBL ID10109382
MeSH IDM0549804

Synonyms (49)

Synonym
HY-14800
rx-103
radezolid
rx-1741
rx-01-667
radezolid (usan/inn)
869884-78-6
D09369
CHEMBL455461
rx-013
rx-o1_667
rx-01_667
rx1741
unii-53pc6lo35w
n-(((5s)-3-(2-fluoro-4'-(((1h-1,2,3-triazol-5-ylmethyl)amino)methyl)biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide
53pc6lo35w ,
acetamide, n-(((5s)-3-(2-fluoro-4'-(((1h-1,2,3-triazol-5-ylmethyl)amino)methyl)(1,1'-biphenyl)-4-yl)-2-oxo-5-oxazolidinyl)methyl)-
n-((3-(2-fluoro-4'-(((1h-1,2,3-triazol-5-ylmethyl)amino)methyl)(1,1'-biphenyl)-4-yl)-2-oxo-5-oxazolidinyl)methyl)acetamide
radezolid [usan:inn]
and rx-01_667
n-{[(5s)-3-(2-fluoro-4'-{[(1h-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
n-[[(5s)-3-[3-fluoro-4-[4-[(1h-triazol-5-ylmethylamino)methyl]phenyl]phenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
CS-0688
radezolid [inn]
radezolid [usan]
radezolid [who-dd]
SCHEMBL1035776
SCHEMBL10109382
n-{ [(5s)-3-(2-fluoro-4'-{[(1h-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
(5s)-n-[3-(2-fluoro-4'-{[(1h-[1,2,3]triazol-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
BTTNOGHPGJANSW-IBGZPJMESA-N
(5s)-n-[3-(2-fluoro-4'-{[(1h-[1,2,3]triazol-4-ylmethyl)-amino]-methyl)-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
n-[[(5s)-3-[2-fluoro-4'-[[(1h-1,2,3-triazol-5-ylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide
EX-A1247
AKOS027326714
mmv688327
DB12339
rx103
Q7280139
n-[[(5s)-3-[3-fluoro-4-[4-[(2h-triazol-4-ylmethylamino)methyl]phenyl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
rd8 ,
gtpl10849
(s)-n-((3-(4'-((((1h-1,2,3-triazol-5-yl)methyl)amino)methyl)-2-fluoro-[1,1'-biphenyl]-4-yl)-2-oxooxazolidin-5-yl)methyl)acetamide
A902025
F84823
MS-27854
DTXSID301007238
n-({(5s)-3-[2-fluoro-4'-({[(1h-1,2,3-triazol-4-yl)methyl]amino}methyl)[1,1'-biphenyl]-4-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
AC-36840

Research Excerpts

Overview

Radezolid is a promising antibiotic of oxazolidinone family. It is able to overcome effect of some linezolid resistance mechanisms of bacterial ribosomes.

ExcerptReferenceRelevance
"Radezolid is a novel biaryloxazolidinone in clinical development which shows improved activity, including against linezolid-resistant strains. "( Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
Appelbaum, PC; Kosowska-Shick, K; Lemaire, S; Tulkens, PM; Van Bambeke, F; Verween, G, 2010)		2.05
"Radezolid is a promising antibiotic of oxazolidinone family, which is able to overcome effect of some linezolid resistance mechanisms of bacterial ribosomes. "( Investigation of radezolid interaction with non-canonical chloramphenicol binding site by molecular dynamics simulations.
Makarov, GI; Reshetnikova, RV, 2021)		2.4

Bioavailability

ExcerptReferenceRelevance
"We have developed a first generation of hybrid sparsomycin-linezolid compounds into a new family of orally bioavailable biaryloxazolidinones that have activity against both linezolid-susceptible and -resistant gram-positive bacteria as well as the fastidious gram-negative bacteria Haemophilus influenzae and Moraxella catarrahalis."( Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
Bhattacharjee, A; Chen, S; Chen, Y; Duffy, E; Farmer, J; Goldberg, J; Hanselmann, R; Ippolito, JA; Johnson, G; Lou, R; Orbin, A; Oyelere, A; Salvino, J; Springer, D; Tran, J; Wang, D; Wu, Y; Zhou, J, 2008)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (225)

Assay IDTitleYearJournalArticle
AID531643Antimicrobial activity against linezolid-resistant Enterococcus faecium A6349 expressing VanA gene2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
AID1611121Antibacterial activity against linezolid-resistant Enterococcus faecalis CLSI-based double dilution method2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design and synthesis of biaryloxazolidinone derivatives containing amide or acrylamide moiety as novel antibacterial agents against Gram-positive bacteria.
AID1692902Antibacterial activity against methicillin-sensitive Staphylococcus aureus2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety.
AID520230Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 03B10692008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID583879Antibacterial activity against laboratory-derived Staphylococcus aureus isolate 29213-1 harboring ribosomal protein L3 Gly155Arg mutant and cfr-containing p42262 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID410114Antimicrobial activity against erm (B) Streptococcus pyogenes msr610 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID519996Antimicrobial activity against Streptococcus pneumoniae harboring mef(A) gene2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533753Antimicrobial activity against linezolid resistant methicillin-susceptible Staphylococcus aureus SA040L after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534246Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected rat fibroblast at 4 mg/liter after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520006Antimicrobial activity against Chlamydia trachomatis isolated from human respiratory tract by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533751Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533971Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA040 infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534507Drug level in human THP1 cells at 250 mg/L after 2 hrs in presence of 50 uM proton inophore monesin relative to control2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID1611122Antibacterial activity against vancomycin-resistant Enterococcus faecium CLSI-based double dilution method2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design and synthesis of biaryloxazolidinone derivatives containing amide or acrylamide moiety as novel antibacterial agents against Gram-positive bacteria.
AID519992Antimicrobial activity against vancomycin-susceptible Enterococcus faecium nosocomial isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID519993Antimicrobial activity against vancomycin-resistant Enterococcus faecium nosocomial isolate2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534238Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected human Calu3 cells at 4 mg/liter after 2 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID1692898Antibacterial activity against Enterococcus2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety.
AID533993Bacteriostatic activity against linezolid-resistant Staphylococcus aureus SA238L infected in HUVEC cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520026Antimicrobial activity against Enterococcus faecium A59592008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534001Bacteriostatic activity against linezolid-resistant Staphylococcus aureus SA238L infected in human epidermal keratinocytes cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID1574837Antibacterial activity against methicillin-sensitive Staphylococcus aureus by broth liquid microdilution method2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design and synthesis of biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety as novel antibacterial agents against Gram-positive bacteria.
AID533994Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in Calu-3 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520000Antimicrobial activity against Moraxella catarrhalis2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533977Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS18 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533950Antimicrobial activity against hospital acquired methicillin-resistant, vancomycin resistant Staphylococcus aureus VRS1 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534518Drug level in human THP1 cells at 50 mg/L after 2 hrs in presence of < 10% fetal calf serum relative to control2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID583705Antibacterial activity against clinical-derived Staphylococcus aureus isolate 42262 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID533955Antimicrobial activity against Staphylococcus aureus infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520222Antimicrobial activity against Enterococcus faecium A96502008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID520009Antimicrobial activity against Staphylococcus aureus A7819 harboring G2576U mutation in 23S rRNA2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID520002Antimicrobial activity against Mycoplasma pneumoniae isolated from human respiratory tract by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534252Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534248Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells at pH 7.4 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID583881Antibacterial activity against laboratory-derived Staphylococcus aureus isolate 29213-3 harboring ribosomal protein L3 deltaPhe127-His146 mutant and cfr-containing p42262 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID520233Antimicrobial activity against Haemophilus influenzae 54A11002008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534241Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected human osteoblast at 4 mg/liter after 2 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID1574839Antibacterial activity against vancomycin-resistant Enterococcus faecium by broth liquid microdilution method2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design and synthesis of biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety as novel antibacterial agents against Gram-positive bacteria.
AID520001Antimicrobial activity against Haemophilus influenzae2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533982Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus ATCC 25923 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID1692897Antibacterial activity against Staphylococcus2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety.
AID519989Antimicrobial activity against coagulase-negative Staphylococcus nosocomial isolate2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID410110Antimicrobial activity against vanB+ expressing Enterococcus faecalis 1069 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID520023Antimicrobial activity against Enterococcus faecalis A63432008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID1692903Antibacterial activity against linezolid-resistant Enterococcus faecalis2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety.
AID583878Antibacterial activity against laboratory-derived Staphylococcus aureus ATCC 29213 harboring cfr-containing p42262 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID533952Antimicrobial activity against Staphylococcus epidermidis SA362 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534508Drug level in human THP1 cells at 10 mg/L after 2 hrs in presence of 50 uM proton inophore monesin relative to control2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID533992Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA238 infected in HUVEC cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520234Antimicrobial activity against Haemophilus influenzae A19502008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534521Drug level in human THP1 cells at 50 mg/L after 2 hrs in presence 10 uM efflux pump inhibitor verapamil relative to control2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID519997Antimicrobial activity against Streptococcus pneumoniae ribosomal mutant2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534522Drug level in human THP1 cells at 50 mg/L after 2 hrs in presence 250 uM efflux pump inhibitor gemfibrozil relative to control2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID534235Bacteriostatic activity against linezolid-resistant Staphylococcus aureus SA238L infected in rat fibroblast cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533970Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS18 infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533949Antimicrobial activity against methicillin-resistant, vancomycin intermediate Staphylococcus aureus NRS18 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534514Drug level in mouse J774 cells at 50 mg/L at pH 6.52010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID520225Antimicrobial activity against Enterococcus faecium A87672008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID520005Antimicrobial activity against Mycoplasma hominis isolated from human respiratory tract by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID520236Antimicrobial activity against Enterococcus faecium A63492008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533969Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS384 infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533948Antimicrobial activity against methicillin-resistant, vancomycin intermediate Staphylococcus aureus NRS52 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID519990Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis nosocomial isolate2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID1574834Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth liquid microdilution method2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design and synthesis of biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety as novel antibacterial agents against Gram-positive bacteria.
AID519994Antimicrobial activity against Streptococcus pneumoniae harboring erm(B) gene by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID519999Antimicrobial activity against Streptococcus pyogenes harboring mef(A) gene2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534517Ratio of drug level for cellular to extracellular region of human PMNC cells at 10 to 50 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID1692896Antibacterial activity against Streptococcus2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety.
AID534006Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in rat fibroblast cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534255Antimicrobial activity against Staphylococcus aureus ATCC 25923 assessed as log reduction in bacterial count at 1 mg/L after 5 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520003Antimicrobial activity against Legionella pneumophila isolated from human respiratory tract by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID531639Antimicrobial activity against Staphylococcus aureus ATCC 292132008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
AID520228Antimicrobial activity against methicillin-resistant Staphylococcus aureus BK 111182008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533983Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus ATCC 33591 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID531638Selectivity ratio of IC50 for rabbit reticulocyte 50S ribosomal subunit to IC50 for Staphylococcus aureus ATCC 29213 50S ribosomal subunit2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
AID410111Antimicrobial activity against vanA+ expressing Enterococcus faecalis A6349 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID533984Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus NRS384 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID519987Antimicrobial activity against methicillin-susceptible Staphylococcus aureus nosocomial isolate2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533968Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 33591 infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533752Antimicrobial activity against methicillin-susceptible Staphylococcus aureus SA040 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533953Antimicrobial activity against Listeria monocytogenes EGD after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID519998Antimicrobial activity against Streptococcus pyogenes2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533985Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus NRS18 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533965Bacteriostatic activity against Listeria monocytogenes EGD infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520229Antimicrobial activity against methicillin-resistant Staphylococcus aureus BK 115122008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID520021Antimicrobial activity against Enterococcus faecalis ATCC 29212-P5 harboring G2576U mutation in 23S rRNA2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533755Antimicrobial activity against hospital acquired methicillin-resistant Staphylococcus aureus SA238 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533957Antimicrobial activity against Listeria monocytogenes infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID519991Antimicrobial activity against vancomycin-resistant Enterococcus faecalis nosocomial isolate2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID1692900Antibacterial activity against Staphylococcus aureus ATCC 292132021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety.
AID534240Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected rat fibroblast at 4 mg/liter after 2 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID410112Antimicrobial activity against methicillin-resistant Staphylococcus aureus 67-0 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID534503Half life in human THP1 cells at 4 mg/L2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID533996Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA238 infected in Calu-3 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520227Antimicrobial activity against methicillin resistant Staphylococcus aureus 67-02008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533975Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 33591 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533956Antimicrobial activity against Staphylococcus epidermidis infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520224Antimicrobial activity against Enterococcus faecium A9621 by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534256Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID531637Inhibition of 50S ribosomal subunit purified from linezolid-,erythromycin-resistant Staphylococcus aureus A7820 with G2576U mutation in 23s rRNA assessed as inhibition of translation using in vitro transcribed mRNA encoding firefly luciferase2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
AID1421221Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth liquid microdilution method2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and antibacterial activity evaluation of novel biaryloxazolidinone analogues containing a hydrazone moiety as promising antibacterial agents.
AID520022Antimicrobial activity against Enterococcus faecalis A63502008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533947Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus NRS384 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520025Antimicrobial activity against Enterococcus faecalis A77892008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533958Antimicrobial activity against Legionella pneumophila ATCC 33153 infected in THP1 cells assessed as log reduction in bacterial count after 48 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520004Antimicrobial activity against Ureaplasma urealyticum isolated from human respiratory tract by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID519995Antimicrobial activity against Streptococcus pneumoniae harboring erm(B) and mef(A) gene2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533754Antimicrobial activity against hospital acquired methicillin-resistant Staphylococcus aureus ATCC 33591 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID410113Antimicrobial activity against erm (B) expressing Streptococcus pneumoniae 02J1258 + L4 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID1574838Antibacterial activity against linezolid-resistant Enterococcus faecalis by broth liquid microdilution method2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design and synthesis of biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety as novel antibacterial agents against Gram-positive bacteria.
AID520024Antimicrobial activity against Enterococcus faecalis A59622008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID519986Antimicrobial activity against Streptococcus pneumoniae nosocomial isolate2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID520028Antimicrobial activity against Enterococcus faecium A63452008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533986Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA040 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID519988Antimicrobial activity against methicillin-resistant Staphylococcus aureus nosocomial isolate2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID410109Antimicrobial activity against Linezolid-resistant Enterococcus faecalis ATCC 29212-P5 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID533964Bacteriostatic activity against Staphylococcus epidermidis infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533999Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in human epidermal keratinocytes cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID583706Antibacterial activity against clinical-derived Staphylococcus aureus isolate harboring ribosomal protein L3 deltaSer145/His146Tyr mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID534243Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected HUVEC cells at 4 mg/liter after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520016Antimicrobial activity against Staphylococcus epidermidis A89342008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533995Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in Calu-3 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534244Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected human Calu3 cells at 4 mg/liter after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533991Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in HUVEC cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533945Antimicrobial activity against Linezolid resistant hospital acquired methicillin-resistant Staphylococcus aureus SA238L after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534002Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in human osteoblasts cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID1692904Antibacterial activity against vancomycin-resistant Enterococcus faecium2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety.
AID520015Antimicrobial activity against Staphylococcus hominis A78282008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534245Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected human keratinocyte at 4 mg/liter after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID1692901Antibacterial activity against methicillin-resistant Staphylococcus aureus2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety.
AID534237Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected HUVEC cells at 4 mg/liter after 2 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520017Antimicrobial activity against Staphylococcus capitis A89352008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID410115Antimicrobial activity against Haemophilus influenzae 1100 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID1421220Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth liquid microdilution method2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and antibacterial activity evaluation of novel biaryloxazolidinone analogues containing a hydrazone moiety as promising antibacterial agents.
AID583876Antibacterial activity against laboratory-derived Staphylococcus aureus isolate 29213-2 harboring ribosomal protein L3 Gly155Arg/Met169Leu mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID534250Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells at pH 7.4 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533962Antimicrobial activity against Legionella pneumophila ATCC 33153 infected in THP1 cells after 48hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533979Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520013Antimicrobial activity against Staphylococcus aureus A87612008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID1611118Antibacterial activity against Staphylococcus aureus ATCC 29213 CLSI-based double dilution method2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design and synthesis of biaryloxazolidinone derivatives containing amide or acrylamide moiety as novel antibacterial agents against Gram-positive bacteria.
AID533976Antimicrobial activity against linezolid-susceptible Staphylococcus aureus NRS384 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534520Drug level in human THP1 cells at 50 mg/L after 2 hrs in presence 60 mM deoxyglucose and 5 mM NaN3 relative to control2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID410118Antimicrobial activity against mef (A) Streptococcus pneumoniae 02J1175 in orally dosed mouse peritonitis model2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID534519Drug level in mouse J774 cells at 50 mg/L after 2 hrs in presence of < 10% fetal calf serum relative to control2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID520235Antimicrobial activity against Staphylococcus aureus A78202008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534242Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected human THP-1 cells at 4 mg/liter after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534000Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA238 infected in human epidermal keratinocytes cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID410116Antimicrobial activity against Haemophilus influenzae A1950 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID520014Antimicrobial activity against Staphylococcus aureus A87272008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534003Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in human osteoblasts cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534004Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA238 infected in human osteoblasts cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520012Antimicrobial activity against Staphylococcus aureus A78172008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533960Antimicrobial activity against Staphylococcus epidermidis infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533972Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534005Bacteriostatic activity against linezolid-resistant Staphylococcus aureus SA238L infected in human osteoblasts cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID1611120Antibacterial activity against methicillin-sensitive Staphylococcus aureus CLSI-based double dilution method2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design and synthesis of biaryloxazolidinone derivatives containing amide or acrylamide moiety as novel antibacterial agents against Gram-positive bacteria.
AID410117Antimicrobial activity against Haemophilus influenzae by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID520031Antimicrobial activity against Enterococcus faecium A81302008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID520007Antimicrobial activity against Chlamydophila pneumoniae isolated from human respiratory tract by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534254Antimicrobial activity against Staphylococcus aureus ATCC 25923 infected in THP-1 cells assessed as log reduction in bacterial count at 1 mg/L after 5 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520232Antimicrobial activity against Streptococcus pneumoniae 02J11752008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID520020Antimicrobial activity against Enterococcus faecalis ATCC 292122008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533978Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA040 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID531641Antimicrobial activity against Enterococcus faecalis ATCC 292122008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
AID533974Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 25923 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534251Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells at pH 5.5 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID531636Inhibition of 50S ribosomal subunit purified from Staphylococcus aureus ATCC 29213 assessed as inhibition of translation using in vitro transcribed mRNA encoding firefly luciferase2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
AID583875Antibacterial activity against laboratory-derived Staphylococcus aureus isolate 29213-1 harboring ribosomal protein L3 Gly155Arg mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID583880Antibacterial activity against laboratory-derived Staphylococcus aureus isolate 29213-2 harboring ribosomal protein L3 Gly155Arg/Met169Leu mutant and cfr-containing p42262 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID1421223Antibacterial activity against linezolid-resistant Enterococcus faecalis by broth liquid microdilution method2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and antibacterial activity evaluation of novel biaryloxazolidinone analogues containing a hydrazone moiety as promising antibacterial agents.
AID583708Antibacterial activity against laboratory-derived Staphylococcus aureus ATCC 29213 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID534515Drug level in mouse J774 cells at 50 mg/L in presence of 50 uM proton inophore monesin relative to control2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID533988Bacteriostatic activity against linezolid-resistant Staphylococcus aureus SA040L infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520018Antimicrobial activity against Staphylococcus aureus pL1502008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534513Drug level in human THP1 cells at 50 mg/L at pH 6.52010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID533963Bacteriostatic activity against Staphylococcus aureus infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534506Drug level in human THP1 cells at 50 mg/L after 2 hrs in presence of 50 uM proton inophore monesin relative to control2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID520027Antimicrobial activity against Enterococcus faecium A59602008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533981Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533966Bacteriostatic activity against Legionella pneumophila ATCC 33153 infected in THP1 cells after 48hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520011Antimicrobial activity against Staphylococcus aureus A8831 harboring U2500A mutation in 23S rRNA2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534249Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP-1 cells at pH 5.5 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534512Drug level in human THP1 cells at 50 mg/L at pH < 7 in presence of 50 uM proton inophore monesin2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID534236Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected human THP-1 cells at 4 mg/liter after 2 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520231Antimicrobial activity against Streptococcus pneumoniae 02J12582008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533954Antimicrobial activity against Legionella pneumophila ATCC 33153 after 48 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533973Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA040L infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534516Ratio of drug level for cellular to extracellular region of human THP-1 cells at 10 to 50 ug/ml2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID520226Antimicrobial activity against Streptococcus pneumoniae PU1071099 harboring 65WR66 deletion in ribosomal protein L4 by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID520223Antimicrobial activity against Enterococcus faecium A89482008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534509Drug level in human THP1 cells at 50 mg/L after 30 mins at pH 62010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID520008Antimicrobial activity against Staphylococcus aureus ATCC 292132008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID534233Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA238L infected in rat fibroblast cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534239Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected human keratinocyte at 4 mg/liter after 2 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534234Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA238 infected in rat fibroblast cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533951Antimicrobial activity against hospital acquired methicillin-resistant, vancomycin resistant Staphylococcus aureus VRS2 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID1574835Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth liquid microdilution method2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design and synthesis of biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety as novel antibacterial agents against Gram-positive bacteria.
AID520030Antimicrobial activity against Enterococcus faecium A6349 harboring G2576U mutation in 23S rRNA2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID533987Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA238 infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533959Antimicrobial activity against Staphylococcus aureus infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533990Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in HUVEC cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533961Antimicrobial activity against Listeria monocytogenes infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534253Bacteriostatic activity against linezolid-susceptible Staphylococcus aureus SA238 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID531642Antimicrobial activity against linezolid-resistant Enterococcus faecalis P52008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
AID534510Drug level in human THP1 cells at 250 mg/L after 30 mins at pH 62010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID583877Antibacterial activity against laboratory-derived Staphylococcus aureus isolate 29213-3 harboring ribosomal protein L3 deltaPhe127-His146 mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID583707Antibacterial activity against clinical-derived Staphylococcus aureus isolate 51312 harboring ribosomal protein L3 deltaMet169-Gly174 mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.
AID520019Antimicrobial activity against Staphylococcus aureus pLXM1 harboring cfr gene2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID1611119Antibacterial activity against methicillin-resistant Staphylococcus aureus CLSI-based double dilution method2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design and synthesis of biaryloxazolidinone derivatives containing amide or acrylamide moiety as novel antibacterial agents against Gram-positive bacteria.
AID534505Half life in human PMNC at 4 mg/L2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID534504Half life in mouse J774 cells at 4 mg/L2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
AID533980Antimicrobial activity against linezolid-resistant Staphylococcus aureus SA040L infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID533967Antimicrobial activity against linezolid-susceptible Staphylococcus aureus ATCC 25923 infected in THP1 cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID531640Antimicrobial activity against linezolid-,erythromycin-resistant Staphylococcus aureus A7820 with G2576U mutation at 23s rRNA2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
AID533998Antimicrobial activity against linezolid-susceptible Staphylococcus aureus SA238 infected in human epidermal keratinocytes cells assessed as log reduction in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID410107Antimicrobial activity against Haemophilus influenzae parent strain RD1 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID533997Bacteriostatic activity against linezolid-resistant Staphylococcus aureus SA238L infected in Calu-3 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID520010Antimicrobial activity against Staphylococcus aureus A8833 harboring U2500A mutation in 23S rRNA2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID1421224Antibacterial activity against vancomycin-resistant Enterococcus faecium by broth liquid microdilution method2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and antibacterial activity evaluation of novel biaryloxazolidinone analogues containing a hydrazone moiety as promising antibacterial agents.
AID533946Antimicrobial activity against community acquired methicillin-resistant Staphylococcus aureus NRS192 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID534247Ratio of drug level for cellular to extracellular region of Staphylococcus aureus infected human osteoblast at 4 mg/liter after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
AID410104Antimicrobial activity against mef (A) expressing Streptococcus pneumoniae 02J1175 by NCCLS method2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
AID520029Antimicrobial activity against Enterococcus faecium A6348 harboring G2576U mutation in 23S rRNA2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
AID1421222Antibacterial activity against methicillin-sensitive Staphylococcus aureus by broth liquid microdilution method2018European journal of medicinal chemistry, Oct-05, Volume: 158Synthesis and antibacterial activity evaluation of novel biaryloxazolidinone analogues containing a hydrazone moiety as promising antibacterial agents.
AID533989Bacteriostatic activity against linezolid-resistant Staphylococcus aureus SA238L infected in THP1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (16.67)29.6817
2010's9 (50.00)24.3611
2020's6 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.66 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection [NCT00646958]Phase 2150 participants (Actual)Interventional2007-12-31Completed
A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of RX-1741 in the Treatment of Adult Patients With Mild to Moderate Severity of Community-Acquired Pneumonia (CAP) [NCT00640926]Phase 2158 participants (Actual)Interventional2007-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00640926 (2) [back to overview]Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC)
NCT00640926 (2) [back to overview]Per Patient Microbiological Response of Eradicated in the Microbiologically Evaluable (ME) Population at Test of Cure (TOC)
NCT00646958 (2) [back to overview]Number of Participants With a Clinical Response of Cure
NCT00646958 (2) [back to overview]Number of Patients With Per-Patient Microbiologic Response of Eradicated

Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC)

Patients were considered cured if all systemic signs and symptoms of CAP present at screening were improved or resolved and no further antibiotic therapy was necessary. In addition, the follow-up chest X-ray was to be either stable or improved. (NCT00640926)
Timeframe: Study days 14-38

InterventionParticipants (Number)
Radezolid 300 mg PO Daily (QD)34
Radezolid 450 mg PO Daily (QD)37
Radezolid 450 mg PO Twice Daily (BID)32

[back to top]

Per Patient Microbiological Response of Eradicated in the Microbiologically Evaluable (ME) Population at Test of Cure (TOC)

The number of ME patients (defined as those CE patients with evidence of 1 or more of 7 key CAP pathogens: S. pneumoniae, H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, and L. pneumophila) with a microbiologic response of eradicated, i.e. either documented eradication of the baseline pathogen(s), or presumed eradication in the setting of clinical cure with no material to culture. (NCT00640926)
Timeframe: Study Days 14-38

InterventionParticipants (Number)
Radezolid 300 mg PO Daily (QD)16
Radezolid 450 mg PO Daily (QD)20
Radezolid 450 mg PO Twice Daily (BID)18

[back to top]

Number of Participants With a Clinical Response of Cure

To qualify as a Cure, participants were required to fulfill the following criteria: all systemic signs and symptoms of uSSSI present at screening were improved or resolved; no further antibiotic therapy was necessary for treatment of uSSSI; and there was no worsening or appearance of new signs and symptoms of uSSSI. (NCT00646958)
Timeframe: Test of Cure (TOC), day 10-20

InterventionParticipants (Number)
Radezolid QD38
Radezolid BID34
Linezolid BID37

[back to top]

Number of Patients With Per-Patient Microbiologic Response of Eradicated

The microbiological response at the patient level was considered Eradicated (documented or presumed)if no pathogens were present in repeat cultures taken from the original site of infection or a clinical response of cure precluded the ability to obtain a culturable specimen. (NCT00646958)
Timeframe: Test of Cure (TOC), day 10-20

InterventionParticipants (Number)
Radezolid QD20
Radezolid BID23
Linezolid BID21

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		2.0410penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		2.4110alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		8.0340C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.0410beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		2.0410cyclic ketone;
erythromycin
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.4520glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		5.05110carbamate ester;
oxazolidinone		metabolite
florfenicol
florfenicol: structure given in first source. florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture.		2.0410organochlorine compound;
organofluorine compound;
secondary alcohol;
secondary carboxamide;
sulfone		antimicrobial agent
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.04109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
puromycin
[no description available]		2.0410puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
monensin
Monensin: An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies.. monensin A : A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle.		2.0510cyclic hemiketal;
monocarboxylic acid;
polyether antibiotic;
spiroketal		antifungal agent;
coccidiostat;
ionophore
linezolid
[no description available]		10.29150acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.3110cyclodextrin
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		2.0410
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.4520macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
tiamulin
tiamulin: 81723 HFU and tiamutin are for fumarate salt; prevents senescence in ascomycete; pleuromutilin derivative; RN given refers to ((3aS-(3aalpha,4beta,5alpha,6alpha,8beta,9alpha,9abeta,10S*))-isomer. tiamulin : A carbotricyclic compound that is pleuromutilin in which the hydroxyacetate group is replaced by a 2-{[2-(diethylamino)ethyl]sulfanyl}acetate group. An antibacterial drug, tiamulin is used in veterinary medicine (generally as its hydrogen fumarate salt) for the treatment of swine dysentery caused by Serpulina hyodysenteriae.		2.0510carbotricyclic compound;
carboxylic ester;
cyclic ketone;
organic sulfide;
secondary alcohol;
semisynthetic derivative;
tertiary amino compound;
tetracyclic diterpenoid		antibacterial drug
hmr 3647
[no description available]		2.0410
gentamicin sulfate
[no description available]		2.0410
tedizolid
DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.		3.930carbamate ester;
organofluorine compound;
oxazolidinone;
primary alcohol;
pyridines;
tetrazoles		antimicrobial agent;
drug metabolite;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Community Acquired Infection
[description not available]		02.0410
Health Care Associated Infection
[description not available]		02.0410
Cross Infection
Any infection which a patient contracts in a health-care institution.		02.0410
Bacterial Infections, Gram-Positive
[description not available]		03.4520
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		03.4520
Group A Strep Infection
[description not available]		02.2510
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		02.2510